PHILADELPHIA — In what ophthalmologists are heralding as a transformative milestone in genetic medicine, a novel non-cutting CRISPR epigenome therapy has successfully restored functional vision in patients suffering from genetic rod-cone retinal dystrophy.
Medical Breakthrough
Clinical Results
Clinical Results
- Non-cutting epigenetic editing modifies chromatin tags without severing double-stranded DNA.
- 85% of treated patients achieved significant improvements on standardized visual acuity and mobility tests.
- Demonstrated durable gene activation with no adverse immunological or off-target effects observed.